Metabolische und psychische Folgen des PCO-Syndroms – Ansätze für Beratung und Therapie

Kernaussagen

• Das Polyzystische Ovarialsyndrom (PCOS) ist eine der häufigsten hormonellen Störungen bei Frauen im reproduktionsfähigen Alter und geht mit Hyperandrogenismus, Zyklusstörungen und Infertilität einher.

• PCOS tritt sowohl bei übergewichtigen wie auch bei schlanken Frauen häufig zusammen mit einer Insulinresistenz auf. Das Risiko für Typ-2-Diabetes und kardiovaskuläre Erkrankungen ist erhöht.

• Frauen mit PCOS haben ein erhöhtes Risiko für Depressionen, Angststörungen und Essstörungen. Das Vorliegen von Essstörungen kann die Umsetzung von Lebensstilinterventionen erschweren.

• Therapeutisch kommen u.a. eine Kombination aus Ernährungsumstellung, Bewegungstherapie und medikamentöser Behandlung in Frage.

• Eine erfolgreiche Behandlung erfordert die interdisziplinäre Zusammenarbeit von Gynäkolog*innen, Endokrinolog*innen/Diabetolog*innen, Diabetesberater*innen/-assistent*innen sowie ggf. Ernährungsfachkräften und Psycholog*innen.

Publication History

Article published online:
24 June 2025

• Literatur

• 1 Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril 2018; 110: 794-809
• 2 Asuncion M, Calvo RM, San Millan JL. et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from spain. J Clin Endo Metab 2000; 85: 2434-2438
• 3 Diamanti-Kandarakis E, Kouli CR, Bergiele AT. et al. A survey of the polycystic ovary syndrome in the greek island of lesbos: hormonal and metabolic profile. J Clin Endo Metab 1999; 84: 4006-4011
• 4 Farah L, Lazenby AJ, Boots LR. et al. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. J Reprod Med 1999; 44: 870-874
• 5 Knochenhauer ES, Key TJ, Kahsar-Miller M. et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southerneastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082
• 6 Teede HJ, Misso ML, Costello MF. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction (Oxford, England) 2018; 33: 1602-1618
• 7 Teede HJ, Tay CT, Laven JJE. et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023; 108: 2447-2469
• 8 Neven ACH, Forslund M, Ranashinha S. et al. Prevalence and accurate diagnosis of polycystic ovary syndrome in adolescents across world regions: a systematic review and meta-analysis. Eur J Endocrinol 2024; 191: S15-S27
• 9 Munro MG, Balen AH, Cho S. et al. The FIGO Ovulatory Disorders Classification System. Fertil Steril 2022; 118: 768-786
• 10 Teede HJ, Tay CT, Laven JSE. et al. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023. Monash University. Accessed March 10, 2025 at: https://doi.org/10.26180/24003834.V1
• 11 Rosenfield RL, Ehrmann DA. The pathogenesis of Polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37: 467-520
• 12 Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endo Metab 1980; 50: 113-116
• 13 Dunaif A, Futterweit W, Segal KR. et al. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174
• 14 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800
• 15 Geisthövel F, Olbrich M, Frorath B. et al. Obesity and hypertestosteronaemia are independently and synergistically associated with elevated insulin concentrations and dyslipidaemia. Hum Reprod 1994; 9: 610-616
• 16 Moghetti P. Insulin resistance: what is its role in the polycystic ovary syndrome?. Curr Opin Endocrinol Diabetes 2002; 9: 444-450
• 17 Schöfl C, Schill T, Geisthövel F. et al. Polyzystisches Ovarialsyndrom und Insulinresistenz. Dtsch Arztebl 2004; 101: A346-A351
• 18 Johnson JE, Daley D, Tarta C. et al. Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta‑analysis. Oncol Lett 2023; 25: 168
• 19 Brutocao C, Zaiem F, Alsawas M. et al. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine 2018; 62: 318-325
• 20 Gnawali A, Patel V, Cuello-Ramírez A. et al. Why are Women With Polycystic Ovary Syndrome at Increased Risk of Depression? Exploring the Etiological Maze. Cureus 2021; 13: e13489
• 21 Thannickal A, Brutocao C, Alsawas M. et al. Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2020; 92: 338-349
• 22 Çoban ÖG, Tulacı ÖD, Adanır AS. et al. Psychiatric Disorders, Self-Esteem, and Quality of Life in Adolescents with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol 2021; 32: 600-604
• 23 Sari SA, Celik N, Uzun Cicek A. Body Perception, Self-Esteem, and Comorbid Psychiatric Disorders in Adolescents Diagnosed with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol 2020; 33: 691-696
• 24 Fernandes BS, Salagre E, Enduru N. et al. Insulin resistance in depression: A large meta-analysis of metabolic parameters and variation. Neurosci Biobehav Rev 2022; 139: 104758
• 25 Lin H, Liu M, Zhong D. et al. The Prevalence and Factors Associated with Anxiety-Like and Depression-Like Behaviors in Women with Polycystic Ovary Syndrome. Front Psychiatry 2021; 12: 709674
• 26 Pfister G, Rømer K. “It's not very feminine to have a mustache”: Experiences of Danish women with polycystic ovary syndrome. Health Care Women Int 2017; 38: 167-186
• 27 Kitzinger C, Willmott J. “The thief of womanhood”: womenʼs experience of polycystic ovarian syndrome. Soc Sci Med 2002; 54: 349-361
• 28 Cassar S, Misso ML, Hopkins WG. et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction 2016; 31: 2619-2631
• 29 Acien P, Quereda F, Matallin P. et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertility & Sterility 1999; 72: 32-40
• 30 Clark A, Thornley B, Tomlinson L. et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13: 1502-1505
• 31 Kataoka J, Tassone EC, Misso M. et al. Weight Management Interventions in Women with and without PCOS: A Systematic Review. Nutrients 2017; 9: 996
• 32 Gibson-Helm M, Teede HJ, Dunaif A. et al. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2017; 102: 604-612
• 33 Snorgaard O, Poulsen GM, Andersen HK. et al. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2017; 5: e000354
• 34 Astrup A, Hjorth MF. Low-Fat or Low Carb for Weight Loss? It Depends on Your Glucose Metabolism. EBioMedicine 2017; 22: 20-21
• 35 Estruch R, Ros E, Salas-Salvadó J. et al. PREDIMED Study Investigators. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018; 378: e34
• 36 WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/9789240015128
• 37 Teede HJ, Tassone EC, Piltonen T. et al. Effect of the combined oral contraceptive pill and/ or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clin Endocrinol (Oxf) 2019; 91: 479-489
• 38 Abdel-Maboud M, Menshawy A, Hasabo EA. et al. The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials. PloS one 2021; 16: 0254412
• 39 Hanjalic-Beck A, Keck C. Metformin for Treatment of the Polycystic Ovarian Syndrome (PCOS). Geburtsh Frauenheilk 2003; 63: 515-523
• 40 Kolodziejczyk B, Duleba AJ, Spaczynski RZ. et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149-1154
• 41 Jensterle M, Janez A, Fliers E. et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update 2019; 25 (04) 504-517
• 42 Pudel V, Westenhöfer J. Ernährungspsychologie. Göttingen: Hogrefe; 1998
• 43 Herpertz S, de Zwaan M, Zipfel S. Handbuch Essstörungen und Adipositas. Heidelberg: Springer; 2008
• 44 Singh NA, Clements KM, Fiatarone Singh MA. The Efficacy of Exercise as a Long-term Antidepressant in Elderly Subjects: A Randomized, Controlled Trial. The Journals of Gerontology 2001; 56: M497-M504
• 45 Blumenthal JA, Babyak MA, Doraiswamy PM. et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med 2007; 69: 587-596
• 46 Bohlmeijer E, Prenger E, Taal E. et al. The effects of mindfulness-based stress reduction therapy on mental health of adults with a chronic medical disease: A meta-analysis. Journal of Psychosomatic Research 2010; 68: 539-544
• 47 Fjorback LO, Arendt M, Ørnbøl E. et al. Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy – a systematic review of randomized controlled trials. Acta Psychiatrica Scandinavica 2011; 124: 102-119